Hybrid Opioid Compounds and Compositions

Abstract

Disclosed are hybrid opioid compounds, mixed opioid salts, compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particularly, in one aspect the hybrid opioid compound includes at least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical compositions, as well as to methods of treating pain in humans using the hybrid compounds and mixed opioid salts.

1 - 22 . (canceled) 
     
     
         23 . A method of treating pain in a human in need thereof, by administering to the human an effective amount of a hybrid opioid compound, or pharmaceutically acceptable salts thereof, comprising:
 a first opioid receptor agonist compound;   a biologically active compound; and   a linker,   wherein the first opioid agonist compound and the second biologically active compound are each bonded to the linker through a covalent bond.   
     
     
         24 . A method of treating pain in a human in need thereof of  claim 23 , wherein the pain is neuropathic pain. 
     
     
         25 . A method of treating pain in a human in need thereof of  claim 23 , wherein the pain is a mixed pain state comprising neuropathic pain and nociceptive pain. 
     
     
         26 . A method of treating pain in a human in need thereof of  claim 23 , wherein the pain is nociceptive pain. 
     
     
         27 . A method of treating fibromyalgia in a human in need thereof, by administering to the human an effective amount of a hybrid opioid compound, or pharmaceutically acceptable salts thereof, comprising:
 a first opioid receptor agonist compound;   a biologically active compound; and   a linker,   wherein the first opioid agonist compound and the second biologically active compound are each bonded to the linker through a covalent bond.   
     
     
         28 . A method of treating seizures in a human in need thereof, by administering to the human an effective amount of a hybrid opioid compound, or pharmaceutically acceptable salts thereof, comprising:
 a first opioid receptor agonist compound;   a biologically active compound; and   a linker,   wherein the first opioid agonist compound and the second biologically active compound are each bonded to the linker through a covalent bond.   
     
     
         29 . A method of treating depression in a human in need thereof, by administering to the human an effective amount of a hybrid opioid compound, or pharmaceutically acceptable salts thereof, comprising:
 a first opioid receptor agonist compound;   a biologically active compound; and   a linker,   wherein the first opioid agonist compound and the second biologically active compound are each bonded to the linker through a covalent bond.   
     
     
         30 . A method of treating central-nervous system disorders in a human in need thereof, by administering to the human an effective amount of a hybrid opioid compound, or pharmaceutically acceptable salts thereof, comprising:
 a first opioid receptor agonist compound;   a biologically active compound; and   a linker,   wherein the first opioid agonist compound and the second biologically active compound are each bonded to the linker through a covalent bond.